NEW YORK (GenomeWeb) – Fluidigm reported after the close of the market Thursday that its third quarter revenues grew 12 percent year over year on strong sales of its mass cytometry products.

For the three months ended Sept. 30, the South San Francisco, California-based life science research tools firm had $24.7 million in revenues compared to $22.2 million a year ago.

Instrument revenue grew 15 percent to $10.5 million from $9.2 million due to increased revenue from mass cytometry instruments, partially offset by decreased revenue from genomics instruments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.